Anavex Life Sciences (US:AVXL) Globenewswire·2025-11-26 12:30Core Insights - Anavex Life Sciences Corp. will present one oral late breaking communication and two poster presentations on blarcamesine at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference in San Diego from December 1-4, 2025 [1][6]. Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, and other CNS disorders [1][9]. - The lead drug candidate, ANAVEX2-73 (blarcamesine), has completed Phase 2a and Phase 2b/3 clinical trials for Alzheimer's disease and has shown potential in treating other CNS disorders [9]. Presentation Details - The presentations will include: 1. Oral Blarcamesine Phase IIb/III Trial confirming significant clinical and quality of life improvements for early Alzheimer's disease patients [5]. 2. Comparison of Oral Blarcamesine to normal cognitive aging, demonstrating alignment with prodromal cognitive aging trajectories [5]. 3. Discussion on advancing Alzheimer's disease care with the convenience of oral blarcamesine [5]. Mechanism of Action - Blarcamesine works by restoring autophagy, which is crucial for cellular homeostasis and may help treat Alzheimer's by activating the brain's recycling process [3]. - The drug has shown clinically meaningful effects in slowing cognitive decline in early Alzheimer's disease patients with an adequate safety profile [3]. Conference Significance - The CTAD Conference is a key event in Alzheimer's disease clinical research, fostering collaboration and dialogue among researchers [4][6]. - The conference will feature discussions on various advancements in Alzheimer's research, including disease-modifying agents and gene therapy [7]. Research Quality - The scientific program of CTAD is supported by a rigorous peer-review abstract selection process, ensuring high-quality research presentations [8].